InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radio frequency technologies. The company offers minimally-invasive aesthetic medical products for procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. InMode Ltd. offers its products directly in the United States, Canada, the United Kingdom, Spain, and India, as well as indirectly through third-party distributors internationally. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Phone972-4909-6313
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$156.36 million
Profitability
Miscellaneous
Employees198
Next Earnings Date5/19/2020 (Estimated)
OptionableNot Optionable
InMode (NASDAQ:INMD) Frequently Asked Questions
What is InMode's stock symbol?
InMode trades on the NASDAQ under the ticker symbol "INMD."
How were InMode's earnings last quarter?
InMode Ltd. (NASDAQ:INMD) issued its quarterly earnings results on Tuesday, February, 18th. The healthcare company reported $0.46 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.39 by $0.07. The healthcare company had revenue of $47 million for the quarter, compared to analyst estimates of $42.48 million. InMode had a net margin of 39.10% and a return on equity of 52.38%. InMode's quarterly revenue was up 63.3% compared to the same quarter last year. During the same period last year, the company posted $0.22 EPS. View InMode's Earnings History.
When is InMode's next earnings date?
What guidance has InMode issued on next quarter's earnings?
InMode updated its FY 2020
Pre-Market earnings guidance on Tuesday, February, 18th. The company provided EPS guidance of 1.85-1.93 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.70. The company issued revenue guidance of $190-198 million, compared to the consensus revenue estimate of $190.58 million.
What price target have analysts set for INMD?
4 brokerages have issued 12 month target prices for InMode's stock. Their forecasts range from $28.00 to $55.00. On average, they anticipate InMode's stock price to reach $45.25 in the next twelve months. This suggests a possible upside of 38.3% from the stock's current price. View Analyst Price Targets for InMode.
What is the consensus analysts' recommendation for InMode?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InMode in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for InMode.
Has InMode been receiving favorable news coverage?
News stories about INMD stock have trended very negative on Friday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. InMode earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned news coverage about the healthcare company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for InMode.
Who are some of InMode's key competitors?
Some companies that are related to InMode include LivaNova (LIVN), CONMED (CNMD), Natus Medical (NTUS), AxoGen (AXGN), Zynex (ZYXI), TransMedics Group (TMDX), Cutera (CUTR), Semler Scientific (SMLR), Viewray (VRAY), BioLife Solutions (BLFS), Stereotaxis (STXS), Rockwell Medical (RMTI), Fonar (FONR), Soleno Therapeutics (SLNO) and Edap Tms (EDAP).
What other stocks do shareholders of InMode own?
Who are InMode's key executives?
InMode's management team includes the folowing people:
- Mr. Moshe Mizrahy, Chairman & CEO (Age 66)
- Mr. Yair Malca, Chief Financial Officer (Age 41)
- Dr. Michael Kreindel, CTO & Director (Age 51)
- Mr. Shakil Lakhani, Pres of North America (Age 35)
- Dr. Spero Theodorou, Chief Medical Officer (Age 47)
When did InMode IPO?
(INMD) raised $75 million in an initial public offering (IPO) on Thursday, August 8th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Barclays, UBS Investment Bank and Canaccord Genuity acted as the underwriters for the IPO and Baird was co-manager.
When did the company's lock-up period expire?
InMode's lock-up period expired on Tuesday, February 4th. InMode had issued 5,000,000 shares in its public offering on August 8th. The total size of the offering was $70,000,000 based on an initial share price of $14.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the end of the lock-up period.
Who are InMode's major shareholders?
InMode's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Penserra Capital Management LLC (0.87%), UBS Group AG (0.34%), Fred Alger Management LLC (0.13%), Alliancebernstein L.P. (0.12%), Ativo Capital Management LLC (0.11%) and Cetera Advisors LLC (0.11%).
Which institutional investors are selling InMode stock?
INMD stock was sold by a variety of institutional investors in the last quarter, including Penserra Capital Management LLC, Alliancebernstein L.P., Jane Street Group LLC, Emerald Advisers LLC, Raymond James & Associates, Steward Partners Investment Advisory LLC and Optimum Investment Advisors.
Which institutional investors are buying InMode stock?
INMD stock was bought by a variety of institutional investors in the last quarter, including UBS Group AG, Cetera Advisors LLC, Oxford Asset Management LLP, Telemus Capital LLC, Acadian Asset Management LLC, Ativo Capital Management LLC, Standard Life Aberdeen plc and ARK Investment Management LLC.
How do I buy shares of InMode?
Shares of INMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is InMode's stock price today?
One share of INMD stock can currently be purchased for approximately $32.71.
How big of a company is InMode?
InMode has a market capitalization of $1.05 billion and generates $156.36 million in revenue each year. The healthcare company earns $61.15 million in net income (profit) each year or $1.60 on an earnings per share basis. InMode employs 198 workers across the globe.View Additional Information About InMode.
What is InMode's official website?
How can I contact InMode?
InMode's mailing address is TAVOR BUILDING SHAAR YOKNEAM POB 533, YOKNEAM L3, 2069200. The healthcare company can be reached via phone at 972-4909-6313 or via email at [email protected]
MarketBeat Community Rating for InMode (NASDAQ INMD)
MarketBeat's community ratings are surveys of what our community members think about InMode and other stocks. Vote "Outperform" if you believe INMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
